company background image
SOT

Societe de Therapeutique MarocaineCBSE:SOT Stock Report

Market Cap

د.م10.8b

7D

1.8%

1Y

n/a

Updated

19 Oct, 2021

Data

Company Financials
SOT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

SOT Overview

Societe de Therapeutique Marocaine S.A., a pharmaceutical company, manufactures and sells medicines in Morocco.

Price History & Performance

Summary of all time highs, changes and price drops for Societe de Therapeutique Marocaine
Historical stock prices
Current Share Priceد.م1,497.00
52 Week Highد.م418.75
52 Week Lowد.م1,750.00
Beta-0.17
1 Month Change-0.86%
3 Month Change21.71%
1 Year Changen/a
3 Year Change276.84%
5 Year Change380.96%
Change since IPO1,022.76%

Recent News & Updates

Shareholder Returns

SOTMA PharmaceuticalsMA Market
7D1.8%0.7%1.0%
1Yn/a89.6%26.4%

Return vs Industry: Insufficient data to determine how SOT performed against the MA Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SOT performed against the MA Market.

Price Volatility

Is SOT's price volatile compared to industry and market?
SOT volatility
SOT Beta-0.17
Industry Beta0.56
Market Beta1

Stable Share Price: SOT is more volatile than 90% of MA stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SOT's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of MA stocks.

About the Company

FoundedEmployeesCEOWebsite
19761,212Lamia Tazihttps://www.sothema.com

Societe de Therapeutique Marocaine S.A., a pharmaceutical company, manufactures and sells medicines in Morocco. It offers antibiotics; and allergology, oncology, cardiology, dental, dermatology, endocrinology, gastroenterology, gynecology, ophthalmology, ENT, pediatric, pulmonology, reanimation, rheumatology, CNS, and urology, as well as other generic drugs. The company offers its products in various forms, such as tablets, capsules, pouches, syrups, suspensions, powders, collyriums, suppositories, creams and pomades, injectable solutions, and self-injectable syringes.

Societe de Therapeutique Marocaine Fundamentals Summary

How do Societe de Therapeutique Marocaine's earnings and revenue compare to its market cap?
SOT fundamental statistics
Market Capد.م10.78b
Earnings (TTM)د.م249.19m
Revenue (TTM)د.م1.94b

43.3x

P/E Ratio

5.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SOT income statement (TTM)
Revenueد.م1.94b
Cost of Revenueد.م1.00b
Gross Profitد.م937.27m
Expensesد.م688.09m
Earningsد.م249.19m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)34.61
Gross Margin48.32%
Net Profit Margin12.85%
Debt/Equity Ratio22.9%

How did SOT perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

16%

Payout Ratio

Valuation

Is Societe de Therapeutique Marocaine undervalued compared to its fair value and its price relative to the market?

43.25x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: SOT (MAD1497) is trading above our estimate of fair value (MAD257.73)

Significantly Below Fair Value: SOT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SOT is poor value based on its PE Ratio (43.3x) compared to the African Pharmaceuticals industry average (9.4x).

PE vs Market: SOT is poor value based on its PE Ratio (43.3x) compared to the MA market (26.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SOT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SOT is overvalued based on its PB Ratio (9.3x) compared to the XF Pharmaceuticals industry average (1.5x).


Future Growth

How is Societe de Therapeutique Marocaine forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Societe de Therapeutique Marocaine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Societe de Therapeutique Marocaine performed over the past 5 years?

12.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SOT has high quality earnings.

Growing Profit Margin: SOT's current net profit margins (12.8%) are lower than last year (14%).


Past Earnings Growth Analysis

Earnings Trend: SOT's earnings have grown by 12.5% per year over the past 5 years.

Accelerating Growth: SOT's earnings growth over the past year (5.9%) is below its 5-year average (12.5% per year).

Earnings vs Industry: SOT earnings growth over the past year (5.9%) underperformed the Pharmaceuticals industry 10%.


Return on Equity

High ROE: SOT's Return on Equity (21.7%) is considered high.


Financial Health

How is Societe de Therapeutique Marocaine's financial position?


Financial Position Analysis

Short Term Liabilities: SOT's short term assets (MAD1.3B) exceed its short term liabilities (MAD743.0M).

Long Term Liabilities: SOT's short term assets (MAD1.3B) exceed its long term liabilities (MAD216.4M).


Debt to Equity History and Analysis

Debt Level: SOT's debt to equity ratio (22.9%) is considered satisfactory.

Reducing Debt: SOT's debt to equity ratio has reduced from 27% to 22.9% over the past 5 years.

Debt Coverage: SOT's debt is well covered by operating cash flow (71.8%).

Interest Coverage: SOT's interest payments on its debt are well covered by EBIT (42.6x coverage).


Balance Sheet


Dividend

What is Societe de Therapeutique Marocaine current dividend yield, its reliability and sustainability?

0.35%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: SOT's dividend (0.35%) isn’t notable compared to the bottom 25% of dividend payers in the MA market (2.22%).

High Dividend: SOT's dividend (0.35%) is low compared to the top 25% of dividend payers in the MA market (4.86%).


Stability and Growth of Payments

Stable Dividend: SOT is not paying a notable dividend for the MA market, therefore no need to check if payments are stable.

Growing Dividend: SOT is not paying a notable dividend for the MA market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: SOT is not paying a notable dividend for the MA market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SOT's dividend in 3 years as they are not forecast to pay a notable one for the MA market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average board tenure


CEO

Lamia Tazi

no data

Tenure

Ms. Lamia Tazi serves as Chairman and Chief Executive Officer at Societe de Therapeutique Marocaine S.A. and its Director since May 17, 2001. Ms. Tazi served as the Managing Director of Pharmacy at Societe...


Board Members

Experienced Board: SOT's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Societe de Therapeutique Marocaine S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Societe de Therapeutique Marocaine S.A.
  • Ticker: SOT
  • Exchange: CBSE
  • Founded: 1976
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: د.م10.778b
  • Shares outstanding: 7.20m
  • Website: https://www.sothema.com

Number of Employees


Location

  • Societe de Therapeutique Marocaine S.A.
  • Z.I. Bouskoura
  • Bouskoura
  • 20180
  • Morocco

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/19 16:30
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.